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ABSTRACT
Nanotechnology is an emerging science with the potential to create new materials and strategies involving 
manipulation of matter at the nanometer scale (<100 nm). With size-dependent properties, nanoparticles 
have introduced a new paradigm in pharmacotherapy – the possibility of cell-targeted drug delivery with 
minimal systemic side effects and toxicity. The present review provides a summary of published findings, 
especially regarding to nanoparticle formulations for lung diseases. The available data have shown 
some benefits with nanoparticle-based therapy in the development of the disease and lung remodeling in 
respiratory diseases. However, there is a wide gap between the concepts of nanomedicine and the published 
experimental data and clinical reality. In addition, studies are still required to determine the potential of 
nanotherapy and the systemic toxicity of nanomaterials for future human use.
Key words: asthma, turberculosis, nanotechnology, lung cancer.
Correspondence to: Patricia Rieken Macedo Rocco
E-mail: prmrocco@biof.ufrj.br
INTRODUCTION
The advent of nanotechnology holds great promise 
to improve health and quality of life. Since Feynman’s 
notorious lecture in 1959, nanotechnologies have 
grown exponentially (Feynman 1992) based on 
miniaturization of materials without affecting 
their properties (Choi et al. 2007). As a result, 
a wide range of nanotechnology-based medical 
applications are being developed. In particular, 
nano-scaled carriers have innovated drug delivery, 
improving biochemical adverse reactions, allowing 
selective targeting of organs, tissue and cells for 
drug delivery, and minimizing exposure of healthy 
tissue to drugs (Bhaskar et al. 2010).
Nanoparticles are defined as microscopic 
particles with at least one dimension <100 nm, or 
<1,000 nm to include aggregates and agglomerates. 
The functional, toxicological and environmental 
impacts of nanoparticles are mainly determined 
by nanoparticle composition, dissolution, surface 
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area, size, size distribution, and shape (Warheit et 
al. 2007, Card et al. 2008). The miniaturization of 
systems has been shown to have many advantages, 
including new materials properties, great increment 
of surface capability due to enlarged surface-volume 
ratio, shortened transport time of molecules, high 
linear flow rate using a tiny sample loading system, 
and almost limitless expansion of detection spot in 
the case of arrays (Bhaskar et al. 2010).
While our understanding of the functioning of 
the human body at the molecular and nanometer 
scale has greatly improved, the development of 
diagnostic and therapeutic options for the treatment 
of severe and chronic diseases has moved at a 
slower pace (Pison et al. 2006, Stone et al. 2007, 
Surendiran et al. 2009). The ability to incorporate 
drugs into nanosystems introduces a new paradigm 
in pharmacotherapy – the possibility of cell-targeted 
drug delivery (Pison et al. 2006, DiMarco et al. 
2010), minimizing systemic side effects and toxicity 
and improving routes of administration (Pison et al. 
2006, Surendiran et al. 2009, DiMarco et al. 2010).
Theoretically, nanoparticles can be tailored to 
reach the right target at the right time. That would mean 
that pathogenic agents such as viruses or bacteria and 
cancer cells could be precisely targeted and treated 
without disturbing healthy tissue (De Jong and Borm 
2008, Griset et al. 2009). However, a major challenge 
of this new therapy is the possibility of side effects 
or a decrease in beneficial effects caused by changes 
in pH and temperature, leading to modifications 
in the properties of drugs. In lungs, the success of 
nanotherapy depends on a number of factors, such as 
route of administration, nanoparticle characteristics 
and toxicity, and physiological aspects of the lung in 
the presence of respiratory disease (Figure 1).
The present review discusses overall aspects 
of nanotechnology as well as the applicability of 
nanoparticle formulations to specifically treat 
pulmonary diseases.
Figure 1 - Factors that can influence nanoparticle drug delivery.
NANOPARTICLE CHARACTERISTICS
A thorough understanding of physiology, mole-
cular biology, biophysics, and cell physiology is 
required in order to search for new generation drug 
carriers, leading us to search for better techniques 
to observe the distribution of these nanoparticles 
in other organs. For that, the spatio-temporal 
distributions of the active compound within the 
body must be monitored. A fair amount of data is 
available following new developments in imaging 
techniques, in which nanoparticles are already well 
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established as contrast enhancers (Bakan et al. 
2000, Harrington et al. 2000, Krause 1999). Real-
time methods for monitoring pharmacokinetics and 
biodistribution (Taylor et al. 2001), multi-photon 
imaging, intracellular fate of aggregates in situ 
(Watson et al. 2005), application of high throughout 
screening methodology to pharmacokinetics (Watt 
et al. 2000), and above all the development of fast 
and efficient methods that allow simultaneous data 
compilation on pharmacokinetics and metabo-
lism have provided the conditions for data 
collection that are qualitatively different and more 
precise than those previously available. All these 
methodological advances are accompanied by the 
development and implementation of new non-
compartmental modeling methods and advanced 
theoretical tools for physiological and metabolic 
models proposals.
It is well known that conventional drugs have 
major limitations, with adverse effects resulting 
from non-specific drug action and lower efficacy 
associa ted with improper or ineffective dosage 
formulation.
ROUTES OF ADMINISTRATION ORAL
The oral route is comfortable for drug administration 
especially when repeated or routine dosing is 
necessary. Nevertheless, the development of oral 
carriers for many proteins remains a challenge 
because the bioavailability of these molecules is 
limited. In fact, most polypeptides and proteins are 
quickly degraded in the gastrointestinal tract by 
proteolytic enzymes, and the intestinal epithelium 
is a barrier to the absorption of hydrophilic drugs 
(DiMarco et al. 2010, Bailey and Berkland 2009).
Numerous investigations have shown 
that nanocarriers can improve the stability of 
therapeutic agents against enzymatic degradation 
and achieve desired therapeutic levels in target 
tissues for the required duration with a lower 
number of doses. Nanoparticle drug-delivery 
systems might ensure an optimal pharmacokinetic 
profile to meet specific needs. Using nanoparticles 
as oral protein carriers might protect the active 
ingredient in the gastrointestinal tract and prolong 
residence time on the mucous membrane. The 
small size of the nano-drug delivery system also 
facilitates transport by enterocytes across the 
intestinal mucosa after administration (DiMarco 
et al. 2010, Mansour et al. 2009).
TRANSDERMAL AND PARENTERAL
There is little evidence that nanoparticles at a 
size exceeding 100 nm cross the skin barrier 
into the dermal compartment. The penetration of 
nanoparticles at a size smaller than 100 nm requires 
further investigation. Moreover, dermal uptake of 
nanoparticles will be an order of magnitude lower 
than uptake via the inhalation or oral routes (Stern 
and McNeil 2008).
Because of the difficulties associated with topical 
and transdermal delivery of proteins, parenteral 
administration is widely employed, despite the many 
complications associated with this route, such as 
local infections. Another disadvantage of parenteral 
administration is that small proteins are quickly 
filtered out by the kidneys. Without an appropriate 
drug carrier, proteins can also cause unwanted 
allergic reactions, be targeted by the immune system, 
and be rapidly degraded (DiMarco et al. 2010).
In this context, Chiaramoni et al. 2010, 
showed that delivery of DNA to liver and kidney 
was possible via the intraperitoneal route using 
non-charged liposomes and polymeric liposomes, 
respectively. Cationic liposomes were able to 
deliver DNA to a wide range of tissues (e.g., liver, 
intestine, kidney, and blood) by the intraperitoneal 
route. In contrast, using subcutaneous inoculation, 
only cationic liposomes were able to deliver 
DNA to blood. This finding underscores the close 
relation between nanoparticles formulation and 
routes of administration.
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LUNG
The lungs are perhaps the oldest known route of 
drug delivery. In Egypt, inhaled vapors were used 
to treat a variety of diseases as early as 1,500 BC. 
Unfortunately, the lungs were soon put aside, 
and it was not until the early 1950s that serious 
consideration was again given to this route, with 
the appearance of the first metered dose inhaler. 
This device was used to locally administer 
albuterol to treat asthma, but offered little 
precision in dose control (Bailey and Berkland 
2009). Since then, promising advances have been 
achieved with the application of nanotechnology 
to particle engineering, leading to innovative 
treatment strategies, including a more favorable 
route for direct drug delivery in respiratory 
diseases that avoids the first-pass metabolism 
(Bur et al. 2009). Nanotechnology is capable 
of producing low-density microstructures for 
delivery of drugs to the deep lung that present 
enhanced dissolution and bioavailability.
In turn, the respiratory tract has several 
unique advantageous anatomical and physio-
logical features. There are approximately 300 million 
alveoli in the lungs, with a surface area that is greater 
than 100m2, and an alveolar epithelium as thin as 
0.1 μm (for comparison: the columnar intestinal 
epithelium is ~20-30 μm). This large surface area, 
combined with an extremely thin barrier between the 
pulmonary lumen and the capillaries and a high blood 
perfusion rate providing direct access to the central 
circulation, creates conditions that are well suited for 
efficient mass transfer. In addition, the lung is less 
aggressive than the gastrointestinal to proteins and 
nucleic acids, even though enzymatic degradation of 
molecules such small peptides may occur in the lungs 
(Bailey and Berkland 2009, Bur et al. 2009).
Conversely, the epithelial barrier in the deep 
lung is quite formidable, with a resistance that 
is 1,200 Ω*cm2 higher in comparison with the 
intestinal mucosa. Not designed for absorption of 
nutrients, the human lung is clearly less equipped 
with transporters and channels than liver and 
intestine (Bur et al. 2009). Despite all these 
limitations, pulmonary delivery is still a promising 
route for nanoparticle administration.
Inhalable forms of insulin have been developed 
to take advantage of systemic drug delivery through 
the lungs, however without success. Despite the 
lack of success of inhaled insulin, much excitement 
surrounds the potential medicinal benefit of inhaled 
therapeutics (McMahon and Arky 2007).
In 2005, the European Centre for Ecotoxicology 
and Toxicology of Chemicals (ECETOC) convened 
a workshop to develop testing strategies to 
establish the safety of nanomaterials. To evaluate 
nanoparticles in terms of human health hazard, 
in vivo techniques should be validated. A Tier 
1 in vivo testing strategy should assess lung 
inflammation, cell proliferation, and histopathology 
of the respiratory tract. A Tier 2 in vivo testing 
should be based on a longer term inhalation study 
to determine particle deposition, translocation, and 
distribution within the body (Warheit et al. 2007).
PROS AND CONS OF USING NANOPARTICLES
An important goal of the pharmaceutical industry is 
to develop therapeutic agents that can be selectively 
delivered to specific areas in the body to maximize 
the therapeutic index. The use of nanosized carriers 
for advanced drug delivery is advantageous because 
these particles protect nanoencapsulated drugs from 
premature degradation, allowing the targeting to 
specific tissue with increased bioavailability, better 
control of absorption, and clearance and drug release.
Nanoparticles have been manufactured from 
various materials, with unique architectures to 
serve as a possible drug vehicle to treat a particular 
disease. Generally, nanoparticles have been made 
of polymers, ceramics, metals, and biological 
materials. Nanoparticles might adopt spherical, 
branched, or shell structures, depending on the 
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particular therapy to be employed. Nevertheless, 
pharmaceutical nanocarriers must be manufactured 
from biocompatible materials, and their quality, 
safety and efficacy have to be demonstrated by 
appropriate pre-clinical and clinical studies (Yih 
and Al-Fandi 2006).
In the lung, deposited particles are removed 
quite rapidly by macrophages. Mucociliary and 
macrophage clearance can only be circumvented 
by particles that are able to cross the mucus layer 
and reach the sol layer below the gel layer (Bur et 
al. 2009). Lai et al. in 2005 reported the permeation 
of 200 nm PEGylated (with polyethylene glycol) 
particles across mucus. Thus, PEGylation seems to 
be a promising approach to bypass the bronchial 
clearance of pharmaceutical particles. Tang et al. 
2009 demonstrated that a biodegradable copolymer 
of poly (sebacic acid) and poly (ethylene glycol) 
rapidly penetrated the mucus barrier in the lungs of 
patients with cystic fibrosis, possibly by the efficient 
partitioning of polyethylene glycol (PEG).
Depending on the site of the disease, specific 
materials should be used in order to reduce toxicity. 
Liposomes are stable and effective vehicles for 
drug delivery, gene therapy and vaccines, and can 
be easily modified by other appropriate ligands, 
resulting in attractive formulations for targeted 
drug delivery (Anabousi et al. 2005, Abu-Dahab 
et al. 2001).
Concerning gene therapy, new concepts 
for the transfer of DNA into the nucleus are of 
special interest. Various polycationic compounds 
(polymers, lipids, inorganic nanoparticles) have 
been used as non-viral transfection agents (Lutten 
et al. 2008). DNA compacted with polycations 
accesses the nucleus of cells more efficiently than 
non-compacted DNA or lipid-DNA complexes. 
However, complexes consisting of only polycation 
and DNA tend to aggregate in tissue fluids. Addition 
of PEG to complexes was shown to influence particle 
characteristics including structure and stabilization, 
preventing aggregation (Ziady et al. 2003).
Unfortunately, high DNA complexation 
efficacy is often associated with toxicity. 
Consequently, nanoparticles formulated from 
biodegradables polymers are being extensively 
studied as a non-viral alternative to polycationic 
polymers. Poly (lactide-co-glycolide-acid) (PLGA), 
a biodegradable polyester, has been recognized for 
its ability to deliver DNA. However, complexation 
and delivery of nucleotides by PLGA nanoparticles 
are limited by their negative charge. As previously 
stated, positive surface charge seems to be essential 
for an effective binding of the negatively charged 
DNA to the carrier (Bur et al. 2009).
In contrast, Harush-Frenkel et al. 2010 
showed increased local and systemic toxic effects 
with cationic nanoparticle based PEG-PLA 
(polylactide). Conversely, anionic nanoparticles 
of similar size were much better tolerated and did 
not present a systemic toxicity effect, although a 
moderate change was noted in platelet count, with 
no clinical significance. Overall, these observations 
suggest that anionic PEG-PLA nanoparticles are 
useful pulmonary drug carriers. Conversely, several 
groups of nanomaterials (i.e. carbon nanotubes, 
carbon black, fullerenes, silica, metals or metal 
oxides) can induce inflammation and/or fibrosis 
in the lung (Liu et al. 2009). Polyamidoamine 
(PAMAM), a group of materials that appear to be 
very promising as nanocarriers for drug delivery, 
can induce autophagic cell death (Li et al. 2009).
NANOPARTICLE THERAPY IN LUNG DISEASES
There are many nanoparticles currently being 
developed for respiratory applications that aim at 
overcoming the limitations of conventional drugs 
(Table I).
However, as previously stated, a number of 
factors can influence the effects of nanoparticles 
in the lung, such as physical characteristics 
and toxicity, routes of administration, and lung 
physiology in the presence of respiratory diseases.
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Once deposited, particles in micrometer 
scale encounter a variety of physicochemical and 
biological barriers. These include mucus barriers 
and macrophages in the alveolar region. Inside 
the peripheral lung, particles must dissolve and 
drug must diffuse through the epithelial barrier 
and into the blood stream. Larger particles, that 
dissolve slowly, are subject to phagocytosis by 
alveolar macrophages and to inertial properties 
and sedimentation in the bronchial region, where 
the drugs that are delivered are likely to have few 
systemic effects (Bailey and Berkland 2009). In 
turn, particles with diameters in nanometer scale 
would be more likely to reach the alveolar region.
In this context, nanoparticles could be 
incorporated into pulmonary formulations to 
enhance systemic bioavailability, improving long-
term drug effects. In addition, many lung diseases 
are prime candidates for nanoparticle therapy, 
such as asthma, tuberculosis, emphysema, cystic 
fibrosis, and cancer. Treating these diseases locally 
avoids first-pass metabolism, eliminates potential 
side effects caused by high systemic concentrations, 
typical of conventional delivery methods, and may 
reduce costs, because smaller doses are employed.
ASTHMA
Asthma, a major public health problem, is charac-
terized by chronic inflammatory disorder of the 
airways associated with airway hyperresponsiveness. 
The chronic inflammation in asthma can lead to 
ultrastructural changes in airways associated with 
airway remodeling. These changes are not completely 
reversed by the current available therapeutic stra-
tegies, such as steroids (Kroegel 2009).
Inhaled steroids are the treatment of choice to 
control asthma, but their pharmacological effect 
tends to be short, no more than 1–2 h. A recent 
study has shown that stealth steroids compacted 
with nanoparticles achieve prolonged and higher 
benefits at the site of airway inflammation compared 
to free steroids (Matsuo et al. 2009). Furthermore, 
budesonide nanoparticle agglomerates demons-
trated a desirable microstructure for efficient lung 
deposition and nanostructure for rapid dissolution of 
poorly water-soluble drugs (El-Gendy et al. 2009). 
STUDY NANOPARTICLE DESCRIPTION USE
Freitas et al. 1998 Respirocytes
Nanodevices that function as red blood cells, 
but with greater efficacy
Delivery of oxygen to tissues
Iga et al. 2007
Quantum dots
Nanocrystals made to fluoresce when 
stimulated by light
Imaging of lung cancer
Fullerenes Water-soluble C60 fullerenes Inhibition of allergic response
Surendiran et al. 2009 INGN401
Nanoparticle formulation of tumor suppression 
gene FUS1
Lung cancer
Surendiran et al. 2009 ABRAXANE ® Albumin bound taxane particles Non-small cell lung cancer
Surendiran et al. 2009 Liposomes
Uni-multilamellar spherical nanoparticles 
made of lipid bilayer membranes
Cancer chemotherapy/ 
gene therapy
Matsuo et al. 2009
Poly PLA homopolymers 
conjugated with PEG
Betamathasone encapsulated by poly PLA 
homopolymers
Asthma
Kimura et al. 2009 PEG-PLGA Nanoparticle compacted with NF-κB Pulmonary arterial hypertension
Beck-Broichsitter et al. 
2010
PLGA and VS(72)-10 Salbutamol-loaded polymeric nanoparticle Respiratory diseases
Saraogi et al. 2010 Gelatin nanoparticles Natural polymer encapsulated with rifampicin Tuberculosis
TABLE I
Nanoparticles used for respiratory applications.
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Smaller nanoparticles also have a more efficient 
action in bronchodilation (Usmani et al. 2005). In this 
line, Bhavna et al.  2009 showed that nanoparticles 
compacted with salbutamol interact more with the 
lung membrane because peripheral deposition and 
mucociliary movement back to tracheo-bronchial 
region are more intense, causing higher and more 
sustained drug concentration in the target area.
One important development in gene transfer 
was the discovery that chitosan (a biocompatible 
cationic polysaccharide derived from crustacean 
shell chitin) in the form of nanoparticles (100–200 
nm) could be used to deliver plasmids. Kumar et al. 
2003 demonstrated that chitosan interferon (IFN)-γ- 
plasmid deoxyribonucleic acid (pDNA) nanoparticle 
therapy effectively reduced the functional and 
immunological abnormalities associated with 
allergen sensitization and challenge. This effect 
was predominantly mediated via a STAT4 signaling 
pathway. Moreover, because of the similarities 
between mice and humans in the T-cell differentiation 
pathway, these results indicated that chitosan IFN-
γ-pDNA nanoparticle may be capable of reversing 
allergic asthma in humans.
The results obtained by Kumar et al. also show 
that intranasal chitosan IFN-γ-pDNA nanoparticle 
therapy may be useful in both prophylaxis and 
treatment of asthma.
In addition, Kong et al. 2008 demonstrated 
that this therapy led to in situ production of IFN- 
γ, reduced inflammation and airway reactivity, 
decreased number of pro-inflammatory CD8+ 
T cells, and inhibition of the antigen-presenting 
activity of dendritic cells in mice.
TUBERCULOSIS
Although potentially curative treatments for 
tuberculosis have been available for almost half a 
century, this disease remains the leading cause of 
preventable deaths in the world today. Nanoparticle-
based drug delivery systems may be considered for 
the treatment of tuberculosis (Gelperina et al. 2005). 
In this line, a single inhalation of aerosolized poly 
(DL-lactideco-glycolide) nanoparticles loaded with 
antitubercular drugs has resulted in therapeutic 
plasma drug levels for up to 6 days in guinea pigs, 
and repeated inhalations were as effective as more 
frequent oral administrations of free drug in treating 
experimental tuberculosis (Pandey et al. 2003). 
Another study reported that a single subcutaneous 
injection of antitubercular drug-containing nano-
particles in mice resulted in therapeutic plasma drug 
levels for up to 32 days, and was more effective at 
reducing bacterial counts in the lungs and spleen 
than was daily oral administration of free drug 
(Pandey and Khuller 2004).
Additionally, Pandey and Khuller studied 
the chemotherapeutic potential of solid lipid 
nanoparticles incorporating rifampicin, isoniazid 
and pyrazinamide against experimental tuberculosis, 
and observed a slow and sustained release of drugs 
from the solid lipid nanoparticles both in vitro and 
in vivo. Inhaled antitubercular drugs encapsulated 
in alginate nanoparticles are more effective than 
free oral drugs (Zahoor et al. 2005).
Finally, in order to enhance drug bioavailability 
by prolonged residence at the site of absorption 
owing to increased epithelial contact, bioadhesive 
drug delivery systems were formulated. Sharma 
et al. (2004) suggested that tuberculosis control 
with reduced drug dosage could be achieved with 
lectin-functionalized poly (lactide-co-glycolide) 
nanoparticles as carriers of antitubercular drugs 
through the oral or aerosol route (Sharma et al. 2004).
LUNG CANCER
Lung cancer is one of the most prevalent types of 
cancer and presents considerable morbidity and 
mortality. Depending on the type and stage of lung 
cancer, chemotherapy may be given as a primary 
treatment or as an adjuvant to surgery. While 
chemotherapeutic agents effectively kill cancer 
cells, their use and hence effectiveness is limited 
by toxicity (Kim et al. 2001, Hitzman et al. 2006). 
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Therefore, most pharmaceutical research 
concerning nanoparticles has been developed in the 
field of oncology. Nanoparticles have been studied 
as a multifunctional strategy, in which a single 
molecule allows detection, diagnosis, imaging, 
cell destruction and delivery of drugs, decreasing 
drug-related side effects. Many nanoparticles can 
be functionalized with different types of molecules 
simultaneously - DNA, RNA, targeting molecules 
and peptides, carbohydrates, and imaging agents 
(Li et al. 2009). Hitzman et al. showed that 
inhalation delivery of 5-fluorouracil in lipid-coated 
nanoparticles to hamsters led to effective local 
targeting and sustained efficacious concentrations 
of 5-fluorouracil at the expected tumor sites.
Guthi et al. 2010 have recently described a 
multifunctional polymeric micelle system encoded 
with a lung cancer-targeting peptide and encapsulated 
with superparamagnetic iron oxide and doxorubicin, 
which potentially enables magnetic resonance 
imaging and target-specific treatment of lung cancer.
PLGA is one of the most widely used 
biode gradable polymers in the production of 
nanoparticles in order to control drug delivery. 
However, this polymer has very high hydro-
phobicity and slow degradation.
In addition, long-term incompatibility with 
blood cells may also represent a problem. However, 
methoxy poly (ethylene glycol)-modified nano-
particles have been shown to provide protection 
against interaction with blood components. In 
addition,  Ma et al. 2010, demonstrated that a PLGA 
copolymer modified with PEG [poly (lactide-co-
glycolide)-d-a-tocopheryl polyethylene glycol 
1,000 succinate] promoted faster drug release in 
comparison with PLGA nanoparticles.
CONCLUSION
This overview summarizes the potential beneficial 
effects of nanoparticle therapy in lung diseases. 
Nanoparticle drug formulations offer many 
advantages over traditional formulations. The use 
of lungs for nanoparticle drug delivery holds great 
promise for the treatment of systemic diseases.
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RESUMO
A nanotecnologia é um campo emergente de ciência 
com o potencial de criar novos materiais e estratégias 
envolvendo a manipulação de materiais em escala 
nanométrica (<100nm). Uma vez que as propriedades 
das nanopartículas dependem do seu tamanho, elas 
vêm introduzido um novo paradigma na farmacoterapia 
– a possibilidade de entregar drogas a células-alvo 
com o mínimo de efeitos colaterais sistêmicos e 
toxicidade. A presente revisão fornece um resumo de 
achados publicados, especialmente no que concerne 
às formulações de nanopartículas para doenças 
pulmonares. Os dados disponíveis têm mostrado 
alguns benefícios da terapia com nanopartículas 
no desenvolvimento da doença e remodelamento 
pulmonar em doenças respiratórias. Entretanto, há uma 
grande diferença entre os conceitos de nanomedicina, 
os dados experimentais publicados e a realidade clínica. 
Além disso, estudos são necessários para determinar o 
potencial da nanoterapia e a toxicidade sistêmica de 
nanomateriais para o uso futuro em humanos.
Palavras-chave: asma, tuberculose, nanotecnologia, 
câncer de pulmão.
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